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Abstract
Purpose: Based on the observation that recurrences of Hodgkin's lymphoma (HL)typically occur in sites of initial nodal involvement the need to concise radiotherapyto only involved nodes that was termed as involved nodal radiotherapy (INRT) or ofinvolved site lymph nodes, involved-site radiation therapy (ISRT) is starting to bewidely accepted to use in early stage HL. We aimed in our study to comparebetween volumetric modulated arc therapy (VMAT) and 3D-conformalradiotherapy (3D-CRT) in radiation of early stage supra-diaphragmatic HL.
Methods: The clinical and dosimetric data of 34 patients affected with stages I andII supra-diaphragmatic HL, treated between January 2011 and September 2015with combined modalities therapy in a single institution were analyzed. Patientsreceived 2-8 cycles of combination chemotherapy ABVD (Adriamycin, Bleomycin,Vinblastine & Dacarbazine) on days 1 and 15 repeated every 28 days. The clinicaltarget volume (CTV) was contoured based on the pre-chemotherapy CT andPET-CT scans. Modification of the CTV was done according to post-chemotherapyanatomical changes. The radiation dose given was 30 Gy/15 fractions. Results:After a median follow up period of 30 months, the progression free survival (PFS)and overall survival (OS) in both groups were 100%. Oropharengeal mucositis wasthe commonest toxicity in both groups. There was no statistically significantdeference between the acute radiation toxicities in both groups. The Dmeanvalue forlung was higher in 3D-CRT than VMAT (12.0 ± 6.1 Gy vs. 9.9 Gy ± 8.6 Gy). For thebreasts volume, the V5Gy was slightly higher for 3D-CRT compared with VMAT at,7.6% and 6.5% respectively. For the heart, V5Gyand V10Gy valueswere higher for theRA than for 3D-CRT accounting for (51.9 ± 28.9%) and (41.0 ± 24.6%) versus (40.0± 25.9% and 30.7 ± 22.5%) respectively. Thyroid gland mean dose was lower forVMAT (21.8 ± 7.7 Gy) than for 3D-CRT (26.8 Gy ± 4.1 Gy) but did not reachstatistically significant value (P = 0.06). Conclusion: Involved-site VMAT techniqueis safe and effective in term of providing excellent local control and survivalfollowing ABVD-based chemotherapy.
Keywords:Hodgkin's lymphoma, Supradiaphragmatic, Radiation Therapy Involvedsite
1. IntroductionThis study compares the dosimetric parameters andclinical outcomes of involved-site volumetric modulatedarc therapy (IS-VMAT) versus 3D-conformal radiationtherapy (3D-CRT) following chemotherapy for patientswith early stage Supradiaphragmatic Hodgkin’s
lymphoma. With larger clinical target volume (CTV),IS-VMAT could yield perfect target volume coverage andsparing of normal tissue. ABVD chemotherapy and IS byeither VMAT or 3D-CRT resulted in a favorable outcomeand minimal toxicity to organs at risk specially the lung.
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Radiation therapy is a major component in the treatmentof Hodgkin’s lymphoma (HL)1; However significantmorbidities and increased incidence of secondmalignancies were detected in long-term survivors withusing of radiation therapy2,3. Based on the observationthat recurrences of HL typically occur in sites of initialnodal involvement4, the need to concise radiotherapy toonly involved nodes that was termed as involved nodalradiotherapy (INRT) or of involved site lymph nodes,involved-site radiation therapy (ISRT) is starting to bewidely accepted to use in early stage HL5,6. The shiftingfrom IFRT to INRT or ISRT decreased the volumes oflungs, breasts and thyroid that receiving high-doseradiation, giving the potential to reduce long-termsecond malignancy risks without effect on local control.7More recently, there has been some interest in arc-basedor rotational therapies in an attempt to overcome someof the limitations associated with fixed field intensitymodulated radiation therapy (IMRT).In arc therapy the radiation is delivered a continuouslyrotating X-ray source allowing a wide beam angle.8, 9VMAT is an evolving radiotherapy technique usingradiation by arcs and inverse planning to deliver highlyconformal radiotherapy, to allow reducing the volumesof organs exposed to high-dose radiation.10 Also, VMATcan delivers the radiation dose in a precise and accurateway in addition to the short delivery time as comparedto the conventional fixed-field IMRT.1, 9 The clinicalworldwide use of VMAT is increasing significantly forpatients having a pre-existing heart disease to minimizefurther cardiac toxicity risks.7, 9The superiority of dose conformity and sparing of organat risk (OAR) are the advantages of VMAT comparedwith conformal radiotherapy (CRT). On other side, incomparing with fixed field IMRT equivalent outcomeswere obtained. However, OAR sparing is improved intreatment of special sites as prostate or cervical cancerwith VMAT.11 The treatment delivery time and reductionof monitor units (MU) are significantly differing betweenVMAT and fixed field IMRT.9 Evaluation of VMAT forearly HL was reported in planning studies and revealedimprovement of planning target volume (PTV) doseuniformity with reduction of the irradiated volume ofheart and lung and allowing sparing of OAR. 10, 12We aimed in our study to compare between VMAT and3D conformal radiotherapy (3D-CRT) in radiation ofinvolved site lymph nodes in cases of early stagesupra-diaphragmatic HL.
2. Methods and MaterialsThe clinical and dosimetric data of 34 patients affectedwith stages I and II supra-diaphragmatic HL, treatedbetween January 2011 and September 2015 withcombined modalities therapy in a single institution wereanalyzed. Study inclusion criteria were, age ≥15 years,
patients with classic HL, prior chemotherapy containingAdriamycin, Bleomycin, Vinblastine and Dacarbazine(ABVD) chemotherapy, complete response afterchemotherapy, involved site radiation volumes, and RTdose of 30 Gy/15 fractions delivered with 3D-CRT orVMAT. The choice between 3D-CRT and VMAT was madefor each patient, considering clinical presentation andspecific needs related to dosimetric plan evaluation.Pre- and Post-chemotherapy assessment by both CT andFDG-PET- CT was done for all patients.
2.1. ChemotherapyPatients with low risk factors received 2-3 cycles ofABVD chemotherapy on days 1 and 15 repeated every 28days. Patients with unfavorable prognostic factors aretreated with 4-8 cycles of ABVD. Radiation therapy wasinitiated within 4 weeks after chemotherapy for allpatients.
2.2. CT simulationPatients were positioned supine with arms along thebody or arms up using special device. The thermoplasticmasks used for immobilization of head and shoulders.Non-contrast CT simulation with a slice thickness of3mm was done.
2.3. Clinical target volumesCT simulation images were fused with images ofpre-chemotherapy CT and PET-CT images using theVarian planning system Eclipse. Drawing of both CTVand PTV was done according to INRT guidelines.6,13,14The CTV was contoured based on the pre-chemotherapyCT and PET-CT scan. Modification of CTV was doneaccording to post-chemotherapy anatomical changes.Organs at risk like heart, lung, spinal cord, and thyroidwere delineated. We used slandered CT window (0) andwidth (500) level for the glandular tissue of the breast.Also, the heart was determined from the root of greatvessels down to the tip of the organ, including the fourcardiac chambers.
2.4. Dosimetric parameters and treatment
planningPatients were given 30 Gy as 2 Gy/fraction over 3 weeksperiod. The PTV received ≥ 95% and maximum dose ≤115% of the prescribed dose. The 3-DCRT plansconsisted of two parallel opposing fields that are shapedwith Multileaf Collimator (MLC). The VMAT plansconsisted of either single full arc (360 °) plan or double –arc plan of 60° angle with starting angles at 150° and330°. The Anisotropic Analytical Algorithm (AAA),Eclipse version 10.0.28.2, photon algorithm was use forall patients. It allows optimization according to biologiccoast functions. Plans were optimized in order to spareOAR as much as possible (particularly lungs, breasts,and heart). Dose constraints for organs at risk are shownin Table 1. Image guidance protocols consisted of dailykilovoltage images or cone beam CT (CBCT) at the first
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three days of treatment followed by weekly imagingthereafter.
Table 1: Dose constrains for organs at risk.Variable Factors ObjectivesPTV DMean 30 GyV˂95% ˂5%V˃107% ˂4%Breast V5 Gy ˂40%V10 Gy ˂25%Lung Dmean ˂14 GyV5 Gy ˂50%V10 Gy ˂35%V20 Gy ≤20%Esophagus Dmean ˂25 GyDMax ˂35 GyHeart Dmean ˂20 GyV5 Gy ˂66%V10 Gy ˂50%Parotids Dmean ˂24 GyThyroid Dmean 18 GyV30 Gy ˂20%The cumulative Dose Volume Histograms (DVHs) wereused for quantitative analysis of the treatmentparameters. These parameters include for PTV (Dmean,V95 and V107) and for OAR, the mean dose andrepresentative Vd according to the dose constrains ofeach organ.
2.5. Follow upDuring radiation, therapy patients were seen weekly forassessment of acute radiation toxicities. Followingradiotherapy patients were checked every 2 months inthe first year and every 4 months after that for threeyears. PET-CT was performed every 6 months. Toxicitieswere scored according to radiation therapy oncologygroup (RTOG) scoring criteria.15 Relapse was defined asthe clinical or radiological appearance of new diseasesites outside radiation fields or the reappearance ofinitially involved lymph nodes on CT scans and/orPET-CT scans.
2.6. Statistical analysisRelapse-free survival was calculated using theKaplan-Meier method16, starting from the time ofdiagnosis. SPSS software Package version 21.0 was usedfor statistical analysis. The log-rank test was used to testthe differences in relapse-free survival (RFS) probabilityfor both 3D-CRT and VMAT. Pearson chi-square test wasused to compare the two treatment plans in terms ofacute toxicity incidence. The Student`s T-test forindependent samples for normally distributedparametric data was used to compare the meansbetween 3D-CRT and VMAT. Values were expressed asmeans± standard deviation according to data
distribution. All P-values reported are two-sided and P <0.05 is considered significant.
3. ResultsThe clinical characteristics for the 34 patients aredescribed in table 2. The clinical features of both groupsare comparable including age, sex, sites involved andtheir number, stage and pathological subtypes. Themedian follow up period for the whole group of patientswas 30 months. For the 3D-CRT group of patients themedian follow up was 32 months (18-50months) and forVMAT group was 27months (18-38months). The PFSand OS in both groups were 100%. Acute radiationtoxicities were summarized in table 3. Oropharengealmucositis was the commonest toxicity in both groups,with grade I mucositis occurring in 6 patients (31.6%)and 3 patients (20%) for 3D-CRT and VMAT techniquesrespectively. Grade II mucositis occurred in only 1patient (6.7%) treated by VMAT and in 3 patients(15.8%) treated with 3D-CRT. Two patients in 3D-CRTgroup developed grade II skin reaction and two patientsin the same group developed grade I radiationpneumonitis. There was no statistically significantdeference between the acute radiation toxicities in bothgroups. The dosimetric data for both groups includingthe PTVs and organs at risk were expressed as meanvalues in Gy± Standard Deviation (SD) and the volume(V) as percentage of the received prescribed dose, asseen in Table 4.
3.1. Target volume coverageFigures 1 and 2 show the dose distribution for twopatient treated by VMAT and 3D-CRT, respectively. Forthe PTV the mean doses in both 3D-CRT and VMAT weresimilar at, 29.5% and 30.5% respectively, with nostatistically significant deference. Also, the dosecoverage for the PTV in both techniques was optimal asindicated by V90%, V95% and V107% values. TheV˂95%	 for	 3D-CRT was 2.4 ± 2.3% and for the VMATwas 3.0 ± 2.6%. For V˃107%	 the	VMAT	showed	higher	value of (3.3%) compared with 3D-CRT (2.9%) but notstatistically significant (P = 0.67).
3.2. LungThe Dmean value for lung was higher in 3D-CRT thanVMAT (12.0 ± 6.1 Gy vs. 9.9 ± 8.6 Gy). However, for thelow doses (V5 & V10) lung volumes were increased inVMAT (46.6% & 35.8%) more than in 3D-CRT (39.8%and 31.3%) respectively. For the lung volumes receivinghigher dose (V20) the mean lung volumes for bothtechniques were similar at, 21.4% and 21.7% for 3D-CRTand VMAT respectively.
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Table 2: Patient's criteria.Characteristics Number 3D-CRTNo. (%) RANo. (%) P-ValueNumber of patients 34 19 (55.9%) 15 (44.1%)AgeRang 15-71 15-57 18-71 0.30Mean 29.8 27.3 32.9SexMale 17 11 (64.7%) 6 (35.3) 0.49Female 17 8 (47.1%) 9 (52.9%)StageIA 4 (11.8%) 1 (5.3%) 3 (20.0%) 0.27IB 2 (9.5%) 1 (5.3%) 1 (6.7%)IIA 25 (73.5%) 14 (73.7%) 11 (73.3%)IIB 3 (8.8%) 3 (15.8%) 0 (0%)Number of involved sites˂ 4 sites 10 (29.4%) 6 (31.6%) 4 (26.7%) 0.53˃ 4 sites 24 (70.6%) 13 (68.4%) 11(73.3%)Involved sitesMediastinum 1 (2.9%) 1 (5.3%) 0 (0.0%) 0.28Bilateral cervical 11 (32.4%) 5 (26.3%) 6 (40.0%)Bilateral cervical/axilla 2 (5.9%) 0 (0.0%) 2 (13.3%)Cervical/Mediastinum 12 (35.3%) 7 (36.8%) 5 (33.3%)Cervical/Mediastinum/axilla 3 (8.8%) 3 (15.8%) 0 (0.0%)Unilateral Cervical 5 (14.7%) 3 (15.8%) 2 (13.3%)Pathologic subtypeLymphocytic depletion 2 (5.9%) 2 (10.5%) 0 (0.0%) 0.08Lymphocytic predominance 7 (20.6%) 3 (15.8%) 4 (26.7%)Mixed cellularity 10 (29.4%) 3 (15.8%) 7 (46.7%)Nodular Sclerosis 15 (44.1%) 11 (57.9%) 4 (26.7%)Chemotherapy regimen2 cycles ABVD 3 (8.8%) 1 (5.3%) 2 (13.3%) 0.193 cycles ABVD 2 (5.9%) 2 (10.5%) 0 (0.0%)4 cycles ABVD 12 (35.3%) 4 (21.1%) 8 (53.3%)
Table 3: Acute Radiation toxicities during treatment with 3D-CRT & RA techniques.Toxicity grades 3D-CRT RA P-valueSkin reactionGrade I 4 (21.1%) 2 (13.3%) 0.19Grade II 2 (10.5%) 0 (0.0%)MucositisGrade I 6 (31.6%) 3 (20.0%) 0.45Grade II 3 (15.8%) 1 (6.7%)NeutropeniaGrade I 10 (52.6%) 3 (20.0%) 0.15Grade II 1 (5.3%) 1 (6.7%)PneumonitisGrade I 2 (10.5%) 1 (6.7%) 0.59Grade II - -
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Table 4: Comparison of doses to treatment volumes and organs at risk.Variable Parameter 3D-CRT RA P-valueMean MeanPTV Dmean (Gy) 29.5±2.8 30.5±0.2 0.18V˂90% 0.4±0.3 0.61±0.5 0.10V˂95% 2.4±2.3 3.0±2.6 0.42V˃107% 2.9±1.8 3.3±3.1 0.67Lung Dmean (Gy) 12.0±6.1 9.9±8.6 0.45V5 Gy 39.8±13.3 46.6±32.7 0.46V10 Gy 31.3±11.7 35.8±30.9 0.61V20 Gy 21.4±9.8 21.7±29.3 0.97Breast V5 Gy 7.6±3.8 6.6±5.6 0.71V10 Gy 4.3±2.61 3.4±3.3 0.60Heart Dmean (Gy) 13.6±8.2 15.7±8.7 0.56V5Gy 40.0±25.9 51.9±28.9 0.32V10 Gy 30.7±22.5 41.0±24.6 0.32Parotid Dmean (Gy) 18.9±2.8 12.0±4.1 0.00Larynx Dmean (Gy) 15.8±9.2 19.4±2.8 0.20Thyroid Dmean (Gy) 26.8±4.1 21.8±7.7 0.06DMax (Gy) 31.9±1.5 29.0±3.6 0.01V30 Gy 53.4±31.3 24.4±17.2 0.03Esophagus Dmean (Gy) 20.9±5.8 15.4±6.4 0.02DMax (Gy) 28.0±8.2 31.0±1.8 0.19
Figure 1: Dose distribution for a three-dimensional radiotherapy (3D-RT) plan in the transversal, sagittal, and coronal planefor a patient with typical planning target volume (PTV) involving the superior mediastinal lymph nodes. Dose volumehistogram data is included.
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Figure 2: Dose distribution for a volumetric modulated arc therapy (VMAT) plan in the transversal, sagittal, andcoronal plane for a patient with planning target volume involving cervical and mediastinal lymph nodes. Dose volumehistogram is illustrated.
3.3. BreastFor the breasts volume, the V5 was slightly higher for3D-CRT compared with VMAT at, 7.6% and 6.5%respectively. Also, the V10 for 3D-CRT was highercompared with VMAT, at 4.3% and 3.4% respectively, butno statistically significant differences.
3.4. HeartFor the heart, the mean dose received was similar in3D-CRT and VMAT (13.6% and 15.7%) respectively. V5and V10 values were higher for the VMAT than for3D-CRT accounting for (51.9 ± 28.9% and 41.0 ± 24.6%)versus (40.0 ± 25.9% and 30.7 ± 22.5%) respectively butnot statistically significant (P = 0.32).
3.5. ParotidsFor the parotids the mean doses were statisticallysignificant lower for VMAT (12.0 ± 4.1 Gy) than 3D-CRT(18.9 ± 2.8 Gy), (P = 0.00).
3.5. LarynxThe mean dose for the larynx was higher for VMAT (19.4± 2.8 Gy) compared with 3D-CRT (15.8 ± 9.2 Gy).
3.5. ThyroidThyroid gland mean dose was lower for VMAT (21.8 ±7.7 Gy) than for 3D-CRT (26.8 ± 4.1 Gy) but did not reachstatistically significant value (P = 0.06).However, TheDmax to thyroid gland in VMAT (29.0 ± 3.6 Gy) was
significantly lower than that for 3D-CRT (31.9 ± 1.5 Gy),(P=0.01). Also, the V30 value was statistically significantlower for VMAT (24.4%) than for 3D-CRT (53.4%), (P =0.03).
3.5. EsophagusFor the esophagus Dmean was significantly lower in RA(15.4 Gy) versus (20.9 Gy) in 3D-CRT (P=0.02).However, Dmaxwere similar in both techniques with 28.0Gy in 3D-CRT and 31.0Gy in VMAT.
4. DiscussionPatients with early-stage HL have about 95% cure ratewith the combined chemo-radiation therapy, thereforethe current and future studies are concerned withreduction of late complications while simultaneouslymaintaining high cure rates. This can be achievedthrough reducing total radiation dose, radiation volume,and/or improvement of radiation techniques.Highly conformal irradiation modalities, utilizingdifferent IMRT approaches, may improve PTV coverageand/or critical organs sparing by improving conformity,resulting theoretically in potentially clinical significantconsequences in patients with Hodgkin’s lymphoma.10,
17-18 In the present study, we aimed to providedosimetric findings and clinical data for the use of rapidArc in comparison to 3D-CRT in limited stage HL
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patients treated by involved-site. Our study shows thatreduction of target volume to IS-PTV most effectivelyimproves OAR sparing, regardless of the radiationtechnique used. Like in our study, the reduction in RTvolumes from the conventional involved-field RT toinvolved-nodal was previously investigated inretrospective studies, without any influence on therelapse pattern in early stage HL. Lu et al. retrospectivelyanalyzed a cohort of 52 patients affected withmediastinal stage I-II HL treated with a combination of 4to 6 cycles ABVD followed by 30 to 40 Gy involved fieldIMRT (step-and-shoot technique).19 The patients wereheterogeneous group with different response tochemotherapy and different total dose (30-40 Gy). Themedian mean lung dose and V20 to the lungs were 13.8Gy and 25.9%, respectively. The median follow-up timewas 36.3 months. Three-year local control, overall andprogression-free survival rates were 97.9%, 100%, and96%, respectively. Two patients experienced grade 3toxicity (mucositis and leukopenia) and 5 patients grade2 mucositis. The second most frequent toxicity was skinreactions (46.2% grade 1 and 5.8% grade 2). No patientsdeveloped ≥grade 2 pneumonitis. Filippi et al.20 analyzedthe clinical data of 90 patients with stage IIA HL treatedwith either involved-site 3D-CRT (54.4%) or IG-IMRT(45.6%) for total dose of 30 Gy after complete responsefollowing 3-4 cycles of ABVD. After a median follow uptime of 54.2 months and 24.1 months for 3D-CRT groupand IG-IMRT group respectively, there were nodifferences in RFS between the two groups. Theincidence of grade 2 mucositis was significantly lower inIG-IMRT than in 3D-CRT (P = 0.43).In our study, thepattern of acute toxicity was similar to the previous twostudies with mucositis being the commonest recordedtoxicity and grade 1 mucositis less common in RA group(20.0%). No patients developed grade 2 radiationpneumonitis. Furthermore, no significant difference inthe toxicity profile between the two groups.From the dosimetric point; cardiac sparing was similarin both 3D-CRT and VMAT the same finding wasreported by Koeck et al.21 in a comparative planningstudy for 20 patients with early unfavorable mediastinalHL. Also, He compared IF-PTV and IN-PTV for bothconventional 3D-CRT and IMRT and observed OAR dosereduction of 20% to 50%, with maximal reduction ofhigh doses to the heart and within low doses to the rightbreast. The same finding was supported previously in aplanning study by Weber et al.10 comparing target fieldreduction from IF-PTV to IN-PTV for IMRT and VMAT for10 female patients with mediastinal HL, and showed asignificant reduction of dose to OAR when using IN-PTVinstead of IF-PTV. As already shown by other authors, insimilar planning comparison studies, different IMRTsolutions were better in terms of lowering mean dosesto certain OAR (thyroid gland, lung, heart and coronaryOstia).12, 13, 22 In this study, the mean doses to the lungs,thyroid, parotids and esophagus were lower in VMATtechnique than in 3D-CRT. Better sparing of the thyroid
gland could reduce the risk of late toxicity ashypothyroidism and second cancer. In addition, nopatients developed grade 2 radiation pneumonitis in ourstudy. In contrast, Girinsky et al.23 demonstrated lungtoxicity of › grade 2 in 10% of patients receiving meanlung dose of 12.8 Gy and 5% lung toxicity with V20 of25% in patients treated for mediastinal HL. There is alsoan important open issue regarding the potential increasein the risk of second malignancies with IMRT and VMAT,secondary to the increased volume of normal tissuesreceiving lower doses. The currently available data forthe risk of radiation-induced secondary tumors are onlytheoretical and somehow controversial, with studiesshowing no differences between 3D-CRT and dedicatedIMRT techniques24 and others indicating a potentialincreased risk 25, 26, especially for breast and lung cancer.However, long-term toxicity of low doses to a largevolume of normal tissues in young patients with highlycurable disease is also a significant concern. Thelimitations of this study include, the small number ofpatients, short follow up period and the late toxicitywere not assessed.Accordingly, every patient should be assessedindividually and the choice of treatment plans andtechnique selected based on clinical needs and priorities.In certain situations, 3D-CRT still represents thestandard choice because of the smaller volume ofirradiated normal tissues. In other patients, IMRT orVMAT may be the preferred technique that, offers asignificantly better sparing of organs at risk, in spite ofthe larger volumes of normal tissues receiving lowdoses. Future clinical and dosimetric studies are neededto recommend different IMRT solutions for differentdisease presentations of HL at diagnosis, with secondcancer risk modeling in the planning process.
5. ConclusionIn early-stage Supradiaphragmatic HL patients,involved-site VMAT technique is safe and effective interm of providing excellent Local control up to 100%,equivalent to the local control achieved with 3D-CRT.
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